Back to top

Secondary immunodeficiencies

These are the most prevalent immunodeficiencies and, as in the previous case, require an expert team that can perform the diagnosis and follow-up of patients. Over the last decade, secondary immunodeficiencies have increased as a consequence of the application of treatments used to modulate the malfunctioning of the immune system in various diseases, such as autoimmune or in haemato-oncological treatments. This can give rise to imbalances and facilitate infections and the onset of acquired immunodeficiencies of this type.

Patients suffering from secondary immunodeficiency generally do so transiently. Our Unit’s specialists indicate whether it is necessary to use antibiotics, immunoglobulins or other treatments through an individualised plan which adapts the treatment to the child’s age, the degree of immunodeficiency and the associated clinical situation. 

We currently treat patients who have a transient or permanent immune deficiency, after or during chemotherapy treatment in oncological pathology, or patients who require immunomodulatory treatments as they suffer from immune-mediated diseases. Early intervention with these patients, through collaboration with professionals who indicate immunosuppressive treatments, makes it possible to avoid complications, which are sometimes severe, and improve patients’ quality of life.

Treatment for secondary immunodeficiencies

Immunoglobulin replacement therapy

The use of this therapy is less common in secondary immunodeficiencies than in primary immunodeficiencies, but it is sometimes necessary. It can be administered at hospital level or subcutaneously to prevent infections.

It is not covered by public health


In immunosuppressed patients, diseases preventable by vaccination are more frequent and serious. A specific vaccination reinforcement plan can prevent possible infections.

It is not covered by public health

Antibiotic prophylaxis

Antibiotics, either prophylactic or early, help to prevent infectious complications. This occurs in moderate or severe immunodeficiency.

It is not covered by public health